Dudediligence.

Beam Therapeutics Inc

BEAMNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

103.3M

on 2026-06-30, from 82.3M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

25M50M75M100MMar2024JunSepDecMar2025$28.48JunSepDecMar2026Jun

Newest

None

No S-3 or F-3 shelf on file in the last 30 months.

None

No at-the-market programme on file in the last 30 months.

Warrants

The 10-Q filed 2026-08-04 is not read yet.

Cash

12.8 quarters

$1.15B on 2026-06-30 ÷ $89.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2025-03-10Public offering incl. 1.40M pre-funded17,556,674$28.48$500.0M424B5 ↗